MAT, ENDP and PALI among pre market gainers
Phunware (NASDAQ:PHUN) +286%. Digital World Acquisition (NASDAQ:DWAC) +94%. Creatd (NASDAQ:CRTD) +56% debuts Camp's website redesign and new product launches Yunhong CTI (NASDAQ:CTIB) +14%. Xiaobai Maimai (NASDAQ:HX) +15%. Salem Media Group (NASDAQ:SALM) +...
Seekingalpha · 6d ago
Second Sight Medical Products US Patent & Trademark Office Abstract For Co.'s 'Method and apparatus to provide safety checks for neural stimulation'
Benzinga · 09/28 13:54
Avoid These 3 Stocks · 08/24 09:31
Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study
Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company re...
Business Wire · 08/11 10:00
Second Sight Obtains New NIH Grant Supplement for Visual Neuroprostheses Study
MT Newswires · 08/11 07:00
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 07/23 20:50
CLOV Stock: What Reddit Investors Are Saying About Clover Health Today as Shares Climb
Investor Place · 07/22 15:31
MRIN Stock: 10 Things for Marin Software Investors to Know About the Popular Meme Stock Today
Investor Place · 07/22 14:53
EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight
Investor Place · 07/22 13:41
SOS, ITRM and PSTV among premarket gainers
India Globalization Capital (IGC) +128% announces issuance of Patent for the treatment of Alzheimer’s disease using THCPainReform (PRFX) +51%.ImmunoPrecise Antibodies (IPA) +41% highlights new data from TATX-03 SARS-CoV-2 Delta studySequential Brands (SQBG...
Seekingalpha · 07/22 13:03
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 07/22 11:34
21 Stocks Moving in Thursday's Pre-Market Session
Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading.
Benzinga · 07/22 11:01
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 07/21 21:38
Second Sight closes 14% higher on European patent supporting artificial vision
Selman Keles/iStock via Getty Images Shares of Second Sight Medical Products (EYES) closed 14% higher after the European Patent Office granted the company's patent application covering field focusing and mapping in an
Seekingalpha · 07/21 20:08
'$EYES Second Sight Medical has been granted European patent number EP2839858 titled "Field focusing and mapping in an electrode array".' - PatentGrants
Benzinga · 07/21 19:36
Second Sight Medical Gains FCC Approval For 'Argus R 2s Glasses A2S01'
Benzinga · 07/06 15:43
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 07/02 19:30
Second Sight raises additional $7.5M from underwriters of stock offering
Second Sight Medical Products ([[EYES]] -2.1%) said underwriters of its previously announced public offering exercised their option in full to buy an additional 1.5M common shares at $5 apiece for $7.5M.In
Seekingalpha · 06/25 19:10
Second Sight Medical Products Announces Closing of Public Offering
Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing o...
Business Wire · 06/25 17:39
Second Sight Medical Products Closes Common Stock Offering
MT Newswires · 06/25 15:08
Webull provides a variety of real-time EYES stock news. You can receive the latest news about Second Sight Med through multiple platforms. This information may help you make smarter investment decisions.
About EYES
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.